ENTA - Enanta Pharmaceuticals, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD

Enanta Pharmaceuticals, Inc.

500 Arsenal Street
Watertown, MA 02472
United States

Full Time Employees132

Key Executives

NameTitlePayExercisedYear Born
Dr. Jay R. LulyPres, CEO & Director998.3kN/A1956
Mr. Paul J. Mellett Jr.Sr. VP of Fin. & Admin. and CFO581.29k657.31k1955
Dr. Yat Sun OrSr. VP of R&D and Chief Scientific Officer636.02k1.99M1952
Mr. Nathaniel S. Gardiner J.D.Sr. VP, Gen. Counsel & Sec.588.49k715.69k1954
Dr. Nathalie AddaSr. VP & Chief Medical Officer620.01kN/A1966
Amounts are as of December 31, 2019 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Enanta Pharmaceuticals, Inc., a biotechnology company, focuses on the research and development of small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, non-alcoholic steatohepatitis, primary biliary cholangitis, and hepatitis B virus. Enanta Pharmaceuticals, Inc. has a collaborative development and license agreement with Abbott Laboratories to identify, develop, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir for the treatment of chronic hepatitis C virus. The company was founded in 1995 and is headquartered in Watertown, Massachusetts.

Corporate Governance

Enanta Pharmaceuticals, Inc.’s ISS Governance QualityScore as of October 4, 2019 is 6. The pillar scores are Audit: 2; Board: 6; Shareholder Rights: 8; Compensation: 4.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.